C-(2,2-Dimethyl-cyclohexyl)-methylamine | 381665-67-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: C-(2,2-Dimethyl-cyclohexyl)-methylamine
• 英文别名: Cyclohexanemethanamine, 2,2-dimethyl-；(2,2-dimethylcyclohexyl)methanamine
• CAS: 381665-67-4
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: YMFOFTIBSUHGNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  C-(2,2-Dimethyl-cyclohexyl)-methylamine 、 4-已氧基苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (+)-N-(2,2-dimethylcyclohexylmethyl)-4-hexyloxybenzamide 、 (-)-N-(2,2-dimethylcyclohexylmethyl)-4-hexyloxybenzamide
  参考文献：
  名称：

  Design and Synthesis of 4-Substituted Benzamides as Potent, Selective, and Orally Bioavailable I_Ks Blockers

  摘要：

  Multiple delayed rectifier potassium currents, including I-Ks are responsible for the repolarization and termination of the cardiac action potential, and blockers of these currents may be useful as antiarrhythmic agents. Modification of compound 5 produced 19(S) that is the most potent IF, blocker reported to date with > 5000-fold selectivity over other cardiac ion channels. Further modification produced 24A with 23% oral bioavailability.

  DOI：

  10.1021/jm015505u

文献信息

• [EN] PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS<br/>[FR] DÉRIVÉS PYRROLIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DU COMPLÉMENT
  申请人：NOVARTIS AG

  公开号：WO2014002054A1

  公开（公告）日：2014-01-03

  The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物(I)的方法，用于制造该发明的化合物，并将其用作眼部疾病治疗的补体途径调节剂。本发明还提供了一种药理活性剂的组合和制药组合物。
• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：——

  公开号：US20020019526A1

  公开（公告）日：2002-02-14

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  一种化合物的结构式，其中R1、R2和R3如上所定义，它们是蛋白酪氨酸激酶的抑制剂，如Janus激酶3，因此可作为免疫抑制剂用于器官移植、狼疮、多发性硬化、类风湿性关节炎、牛皮癣、1型糖尿病和糖尿病并发症、癌症、哮喘、特应性皮炎、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病和其他自身免疫疾病的治疗。
• Pyrrolo [2,3-D] pyrimidine compounds
  申请人：Pfizer Inc.

  公开号：US20030212273A1

  公开（公告）日：2003-11-13

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

  化合物的公式为1，其中R1，R2和R3的定义如上所述，它们是蛋白酪氨酸激酶的抑制剂，例如Janus Kinase 3，并且作为免疫抑制剂用于器官移植，狼疮，多发性硬化症，类风湿性关节炎，牛皮癣，1型糖尿病和糖尿病并发症，癌症，哮喘，特应性皮炎，自身免疫性甲状腺疾病，溃疡性结肠炎，克罗恩病，阿尔茨海默病，白血病和其他自身免疫性疾病的有用治疗方法。
• PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
  申请人：NOVARTIS AG

  公开号：US20150190457A1

  公开（公告）日：2015-07-09

  The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供一种式（I）的化合物，一种制造本发明化合物的方法，以及其作为补体途径调节剂治疗眼部疾病的治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
  申请人：Pfizer Products Inc.

  公开号：EP1087970B1

  公开（公告）日：2004-04-28